These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 23010833)

  • 1. Trichomegaly of the eyelashes during therapy with epidermal growth factor receptor inhibitors: report of 3 cases.
    Fabbrocini G; Panariello L; Cacciapuoti S; Bianca D; Ayala F
    Dermatitis; 2012; 23(5):237-8. PubMed ID: 23010833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.
    Mitchell EP; Perez-Soler R; Van Cutsem E; Lacouture ME
    Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):4-9. PubMed ID: 18154212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trichomegaly following treatment with gefitinib (ZD1839).
    Pascual JC; Bañuls J; Belinchon I; Blanes M; Massuti B
    Br J Dermatol; 2004 Nov; 151(5):1111-2. PubMed ID: 15541102
    [No Abstract]   [Full Text] [Related]  

  • 4. [Cutaneous side effects of EGFR inhibitors--appearance and management].
    Wollenberg A; Kroth J; Hauschild A; Dirschka T
    Dtsch Med Wochenschr; 2010 Jan; 135(4):149-54. PubMed ID: 20101558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [EGFR (epidermal growth factor receptor) inhibitor-associated skin disorders in tumor therapy].
    Reimer G; Brudler O; Heinrich B; Bangerter M
    MMW Fortschr Med; 2008 Dec; 150(49-50):37-8, 40. PubMed ID: 19133368
    [No Abstract]   [Full Text] [Related]  

  • 6. Cutaneous adverse events of epidermal growth factor receptor inhibitors: A retrospective review of 99 cases.
    Chanprapaph K; Pongcharoen P; Vachiramon V
    Indian J Dermatol Venereol Leprol; 2015; 81(5):547. PubMed ID: 25994883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
    Ocvirk J; Cencelj S
    J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
    Štulhofer Buzina D; Martinac I; Ledić Drvar D; Čeović R; Bilić I; Marinović B
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):70-2. PubMed ID: 27149134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
    Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
    J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cetuximab-associated elongation of the eyelashes: case report and review of eyelash trichomegaly secondary to epidermal growth factor receptor inhibitors.
    Cohen PR; Escudier SM; Kurzrock R
    Am J Clin Dermatol; 2011 Feb; 12(1):63-7. PubMed ID: 20726623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The management of EGFR inhibitor adverse events: a case series and treatment paradigm.
    Wnorowski AM; de Souza A; Chachoua A; Cohen DE
    Int J Dermatol; 2012 Feb; 51(2):223-32. PubMed ID: 22250636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cutaneous side effects of EGF receptor inhibitors].
    Nassar D; Soutou B; Aractingi S
    Bull Cancer; 2009 Dec; 96 Suppl():S85-91. PubMed ID: 20034874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies.
    Segaert S; Tabernero J; Chosidow O; Dirschka T; Elsner J; Mancini L; Maughan T; Morere JF; Santoro A; Sobrero A; Van Cutsem E; Layton A
    J Dtsch Dermatol Ges; 2005 Aug; 3(8):599-606. PubMed ID: 16033478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nursing management of epidermal growth factor receptor inhibitor-induced toxicities.
    Dunsford J
    Clin J Oncol Nurs; 2008 Jun; 12(3):405-7. PubMed ID: 18515238
    [No Abstract]   [Full Text] [Related]  

  • 15. Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.
    Wu PA; Balagula Y; Lacouture ME; Anadkat MJ
    Curr Opin Oncol; 2011 Jul; 23(4):343-51. PubMed ID: 21537180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erlotinib-induced trichomegaly in a male patient with pancreatic cancer.
    Saif MW; Gnanaraj J
    Cutan Ocul Toxicol; 2010 Mar; 29(1):62-6. PubMed ID: 19954400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent hair growth during treatment with the EGFR inhibitor erlotinib.
    Alexandrescu DT; Kauffman CL; Dasanu CA
    Dermatol Online J; 2009 Mar; 15(3):4. PubMed ID: 19379648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study.
    Yalici-Armagan B; Ayanoglu BT; Demirdag HG
    Cutan Ocul Toxicol; 2019 Sep; 38(3):261-266. PubMed ID: 31010330
    [No Abstract]   [Full Text] [Related]  

  • 19. Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions.
    Amitay-Laish I; David M; Stemmer SM
    Oncologist; 2010; 15(9):1002-8. PubMed ID: 20709888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors.
    Agero AL; Dusza SW; Benvenuto-Andrade C; Busam KJ; Myskowski P; Halpern AC
    J Am Acad Dermatol; 2006 Oct; 55(4):657-70. PubMed ID: 17010747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.